Clinical trial
Efficacy & Safety of Quetiapine Fumarate (SEROQUEL) & Placebo in the Treatment…
NCT00085891 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00085891 |
|---|---|
| Title | Efficacy & Safety of Quetiapine Fumarate (SEROQUEL) & Placebo in the Treatment of Acutely Ill Patients With Schizophrenia |
| Official title | A 6-Week, Multicenter, Double-Blind, Double-Dummy, Randomized Comparison of the Efficacy and Safety of Sustained-Release Formulation Quetiapine Fumarate (SEROQUEL) and Placebo in the Treatment of Acutely Ill Patients With Schizophrenia |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | Quetiapine Fumarate |
| Enrollment | 535 |
| Start date | Jun 1, 2004 |
| Completion | Sep 1, 2005 |
| First posted | Jun 18, 2004 |
| Last update posted | Mar 25, 2009 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: